AlphAIAlphAI — Financial news for AI agents
investing.comOCT 301 min read$DXCM

Raymond James raises DexCom stock price target to $97 on U.S. growth

Raymond James raised its price target for DexCom (DXCM) to $97 from $94, citing strong U.S. sales growth and margins. The stock trades at $79.93, with a Fair Value estimate suggesting upside. DexCom announced a new share buyback program and raised its full-year outlook, reporting Q3 2026 earnings of $0.73 per share and revenue of $1.34 billion, both exceeding expectations.

Original reporting
investing.com
Published Oct 30, 2026, 9:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 9:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DXCM
Bullish
high confidence
Mentioned
$DXCM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DXCMBullishMed
01

Why it matters

The combination of earnings beat and analyst upgrade is likely to attract short‑term buying, supporting a price rally.

02

Market read

DexCom's strong earnings and upgraded target could drive a near‑term rally, with spill‑over optimism for the broader CGM market.

03

What to watch

Potential slowdown in non‑U.S. markets and competitive pressure from emerging CGM rivals.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

DexCom reported Q3 2026 earnings that beat expectations and received a price‑target raise from Raymond James.

Company-level read

Ticker impact

$DXCMBullishHigh confidence
Context

Raymond James raised its price target on DexCom to $97 and reported better‑than‑expected Q3 earnings of $0.73 EPS and $1.34 B revenue.

Expected impact

likely upward pressure as investors price in the higher target and earnings beat

Evidence & confidence

The new $97 target is above current price (~$80) and earnings beat signals continued growth, prompting buying interest.

Market effects

Sector

Positive for the diabetes device sector, may lift peers like Abbott (ABT) and Medtronic (MDT).

Regional

U.S. market focus, limited regional effect.

Global

Modest, as DexCom is a niche player in global diabetes monitoring.

Counterpoint

What could challenge this read

If the share‑buyback program exhausts cash, growth could stall, limiting upside.

Key entities

  • company
    DexCom

    Medical device maker specializing in continuous glucose monitoring.

  • analyst_firm
    Raymond James

    Equity research firm that raised DexCom's price target.

Read at source← All news

Related articles

NOV 1
$DXCMHighAI 8/10

DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory

DexCom reported Q3 revenue of $1.34B, beating estimates by 1.2%, and adjusted EPS of $0.73, beating by 8.3%. The company raised its full-year revenue guidance to $5.23B. DexCom saw U.S. market share gains, driven by clinical trial results and new product launches, including the G7 15 Day system and a redesigned Stelo app. Operational improvements and expansion into international markets also contributed to margin growth.

finance.yahoo.com2 min
OCT 30
$DXCMHighAI 8/10

Dexcom (DXCM) Q3 2026 Earnings Call Transcript

Dexcom (DXCM) reported Q3 2026 revenue growth of 11%, with U.S. revenue up 14%. The company gained market share, driven by strong CGM demand and positive clinical trial results. Dexcom expects CMS to announce a type 2 non-insulin coverage decision this year, supported by the CONNECT study. The company also launched a redesigned Stelo app and advanced the rollout of its G7 15 Day system.

finance.yahoo.com2 min
OCT 30
$DXCMHighAI 8/10

DexCom Inc (DXCM) Q3 2026 Earnings Call Highlights: Double-Digit Revenue Growth

DexCom Inc (DXCM) reported Q3 2026 earnings, highlighting double-digit revenue growth and strong margins. CEO Jake Leach and CFO Jereme Sylvain addressed pricing, Medicare coverage, and product launches. The company raised full-year 2026 revenue guidance to $5.20B-$5.25B and adjusted EBITDA margin guidance to ~32%. DexCom also announced a European distributor acquisition, expected to close in 2027.

finance.yahoo.com2 min
OCT 29
$DXCMMed

What DexCom (DXCM) Said on Its Q3 Earnings Call

DexCom (DXCM) reported Q3 earnings, citing gross-margin improvements from manufacturing efficiencies and lower costs. The company expects near-term margin pressure due to Ireland facility ramp-up. DexCom ended Q3 with $1.8B in cash, $900M in free cash flow, and completed $1B in stock repurchases. Management anticipates Medicare coverage expansion for type 2 diabetes CGM in mid-2027, supported by positive clinical trial results.

finance.yahoo.com6 min